Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 629 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 629 shares of DexCom stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now owns 68,212 shares in the company, valued at $8,611,765. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Jon Brown also recently made the following trade(s):

• On Thursday, March 28th, Michael Jon Brown sold 2,624 shares of DexCom stock. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96.

DexCom Trading Up 0.6 %

Shares of DexCom stock traded up $0.77 during trading on Thursday, hitting $126.65. The stock had a trading volume of 2,311,384 shares, compared to its average volume of 3,046,284. The stock has a 50 day simple moving average of $131.68 and a 200 day simple moving average of $119.57. The company has a market capitalization of $50.37 billion, a PE ratio of 80.84, a P/E/G ratio of 2.18 and a beta of 1.23. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. On average, research analysts expect that DexCom, Inc. will post 1.77 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on DXCM shares. Canaccord Genuity Group boosted their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Citigroup boosted their price target on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada started coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Raymond James lifted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. DSM Capital Partners LLC purchased a new position in DexCom during the fourth quarter valued at approximately $28,000. Riverview Trust Co acquired a new stake in DexCom in the first quarter valued at approximately $32,000. Valley National Advisers Inc. lifted its stake in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. MV Capital Management Inc. lifted its stake in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Finally, Smithfield Trust Co lifted its stake in DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 165 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.